{"a":[{"_":"Novartis CEO brushes off oral PCSK9 competition as Leqvio drives Q2 growth","$":{"href":"/pharma/novartis-ceo-brushes-oral-pcsk9-competition-leqvio-drives-q2-momentum","hreflang":"en"}}]}

RegulatoryapprovedLeqvioLipfendraPositive

AI Analysis

Summary

Novartis CEO expressed confidence in Leqvio's long-term potential despite Merck's newly approved oral PCSK9 inhibitor Lipfendra entering the market. The statement was made during Novartis' Q2 earnings discussion.

Outcome Details

Merck's oral PCSK9 inhibitor Lipfendra newly approved

Importance:4/10

Sentiment:

0.30

competitive_landscapePCSK9_inhibitorcholesterol_drugQ2_earnings

Related Companies

$NVS

Read the original article

Published by FiercePharma on July 21, 2026 10:16 AM

Read Original